AstraZeneca and Amgen's EoE Treatment Shows Positive Trial Results

AstraZeneca and Amgen have announced positive top-line results from the phase 3 Crossing trial of tezepelumab in patients living with eosinophilic esophagitis (EoE). The companies, which are collaborating on the development and commercialization of the treatment, said tezepelumab showed 'statistically significant and clinically meaningful' improvements across both co-primary and all key secondary endpoints at week 24, sustained through week 52 in both doses tested.

The trial's co-primary endpoints were histologic remission and the frequency and severity of dysphagia (difficulty swallowing) compared to placebo. Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen, said: 'Tezspire improved both the underlying inflammation and the swallowing difficulties that can make eosinophilic esophagitis so disruptive for patients.'

EoE is a chronic and progressive epithelial-driven inflammatory disorder of the esophagus affecting more than 470,000 people in the US, with the prevalence increasing five-fold since 2009. The treatment is currently approved for severe asthma in over 70 countries, including the US, EU, China, Japan, and others.